These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 7744521)

  • 21. Towards antigen-specific apheresis of pathogenic autoantibodies as a further step in the treatment of myasthenia gravis by plasmapheresis.
    Zisimopoulou P; Lagoumintzis G; Kostelidou K; Bitzopoulou K; Kordas G; Trakas N; Poulas K; Tzartos SJ
    J Neuroimmunol; 2008 Sep; 201-202():95-103. PubMed ID: 18667243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current trends in the management of myasthenia gravis: plasmapheresis and immunosuppressive therapy.
    Pollard JD; Basten A; Hassall JE; Kronenberg H; Cobcroft R; Dawkins R
    Aust N Z J Med; 1980 Apr; 10(2):212-7. PubMed ID: 6930213
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of myasthenia gravis with dropped head: a report of 2 cases and review of the literature.
    Tamai M; Hashimoto T; Isobe T; Sato H; Doden T; Nakano T
    Neuromuscul Disord; 2015 May; 25(5):429-31. PubMed ID: 25747003
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Semi-selective immunoadsorption treatment in myasthenia gravis.
    Splendiani G; Passalacqua S; Barbera G; Sturniolo G; Costanzi S; Fulignati P; Casciani CU
    Biomater Artif Cells Immobilization Biotechnol; 1992; 20(5):1145-51. PubMed ID: 1457688
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antigen-specific immunoadsorption of anti-acetylcholine receptor antibodies from sera of patients with myastenia gravis.
    Sun C; Meng F; Li Y; Jin Q; Li H; Li F
    Artif Cells Blood Substit Immobil Biotechnol; 2010 Apr; 38(2):99-102. PubMed ID: 20196680
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Plasmapheresis in patients with myasthenia gravis].
    Konishi T
    Nihon Rinsho; 2008 Jun; 66(6):1165-71. PubMed ID: 18540364
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunoadsorption apheresis versus intravenous immunoglobulin therapy for exacerbation of myasthenia gravis.
    Yasuda M; Uzawa A; Ozawa Y; Kojima Y; Onishi Y; Akamine H; Kuwabara S
    Scand J Immunol; 2022 Feb; 95(2):e13122. PubMed ID: 34796975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antigen-specific immunoadsorption of MuSK autoantibodies as a treatment of MuSK-induced experimental autoimmune myasthenia gravis.
    Lazaridis K; Baltatzidou V; Tektonidis N; Tzartos SJ
    J Neuroimmunol; 2020 Feb; 339():577136. PubMed ID: 31855721
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunoadsorption plasmapheresis for severe generalised myasthenia gravis.
    Ichikawa M; Koh CS; Hata Y; Tohyama M; Tsuno T; Komiyama A
    Arch Dis Child; 1993 Aug; 69(2):236-8. PubMed ID: 8215529
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antigen-specific apheresis of autoantibodies in myasthenia gravis.
    Lazaridis K; Zisimopoulou P; Lagoumintzis G; Skriapa L; Trakas N; Evangelakou P; Kanelopoulos I; Grapsa E; Poulas K; Tzartos S
    Ann N Y Acad Sci; 2012 Dec; 1275():7-12. PubMed ID: 23278571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term treatment of myasthenia gravis with immunoadsorption.
    Haas M; Mayr N; Zeitlhofer J; Goldammer A; Derfler K
    J Clin Apher; 2002; 17(2):84-7. PubMed ID: 12210711
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum Acetylcholine Receptor Antibodies Before the Clinical Onset of Myasthenia Gravis.
    Strijbos E; Verschuuren JJGM; Kuks JBM
    J Neuromuscul Dis; 2018; 5(2):261-264. PubMed ID: 29865092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Deficiencies in anti-acetylcholine receptor antibody measurement in myasthenia gravis.
    Clarke CE; Shepherd DI; Yuill GM; Smaje JC; Wilson PB
    J Neurol Neurosurg Psychiatry; 1991 May; 54(5):454-6. PubMed ID: 1865211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-MuSK positivity on plasmapheresis liquid in a double seronegative myasthenia gravis patient.
    Renard D; Candon S; Jacob M; Trusson R; Reboul P
    Acta Neurol Belg; 2018 Mar; 118(1):119-120. PubMed ID: 28608313
    [No Abstract]   [Full Text] [Related]  

  • 35. Plasmapheresis in the treatment of myasthenia gravis.
    Lenzhofer R; Graninger W; Dittrich C; Mamoli B; Zeitlhofer J; Pateisky K
    Wien Klin Wochenschr; 1983 Apr; 95(8):266-71. PubMed ID: 6603717
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Purification of anti-acetylcholine receptor antibody from patients with myasthenia gravis.
    Lang B; Vincent A; Newsom-Davis J
    J Immunol Methods; 1982; 51(3):371-81. PubMed ID: 7108235
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Myasthenia gravis and antiacetylcholine receptor antibody (author's transl)].
    Ota M; Hayashi K
    Horumon To Rinsho; 1979 Aug; 27(8):833-42. PubMed ID: 385178
    [No Abstract]   [Full Text] [Related]  

  • 38. Cell-Based Versus Enzyme-Linked Immunosorbent Assay for the Detection of Acetylcholine Receptor Antibodies in Chinese Juvenile Myasthenia Gravis.
    Yan C; Li W; Song J; Feng X; Xi J; Lu J; Zhou S; Zhao C
    Pediatr Neurol; 2019 Sep; 98():74-79. PubMed ID: 31307830
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Specific removal of autoantibodies by extracorporeal immunoadsorption ameliorates experimental autoimmune myasthenia gravis.
    Lazaridis K; Dalianoudis I; Baltatzidi V; Tzartos SJ
    J Neuroimmunol; 2017 Nov; 312():24-30. PubMed ID: 28912035
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transient neonatal myasthenia gravis in a baby born to a mother with new-onset anti-MuSK-mediated myasthenia gravis.
    O'carroll P; Bertorini TE; Jacob G; Mitchell CW; Graff J
    J Clin Neuromuscul Dis; 2009 Dec; 11(2):69-71. PubMed ID: 19955986
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.